Literature DB >> 34676283

Enhanced recovery after surgery (ERAS) in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): a cross-sectional survey.

Geetu Bhandoria1, Sohan Lal Solanki2, Mrugank Bhavsar3, Kalpana Balakrishnan4, Cherukuri Bapuji5, Nitin Bhorkar6, Prashant Bhandarkar7, Sameer Bhosale8, Jigeeshu V Divatia2, Anik Ghosh9, Vikas Mahajan10, Abraham Peedicayil11, Praveen Nath12, Snita Sinukumar13, Robin Thambudorai14, Ramakrishnan Ayloor Seshadri15, Aditi Bhatt16.   

Abstract

OBJECTIVES: Enhanced recovery after surgery (ERAS) protocols have been questioned in patients undergoing cytoreductive surgery (CRS) with/without hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancies. This survey was performed to study clinicians' practice about ERAS in patients undergoing CRS-HIPEC.
METHODS: An online survey, comprising 76 questions on elements of prehabilitation (n=11), preoperative (n=8), intraoperative (n=16) and postoperative (n=32) management, was conducted. The respondents included surgeons, anesthesiologists, and critical care specialists.
RESULTS: The response rate was 66% (136/206 clinicians contacted). Ninety-one percent of respondents reported implementing ERAS practices. There was encouraging adherence to implement the prehabilitation (76-95%), preoperative (50-94%), and intraoperative (55-90%) ERAS practices. Mechanical bowel preparation was being used by 84.5%. Intra-abdominal drains usage was 94.7%, intercostal drains by 77.9% respondents. Nasogastric drainage was used by 84% of practitioners. The average hospital stay was 10 days as reported by 50% of respondents. A working protocol and ERAS checklist have been designed, based on the results of our study, following recent ERAS-CRS-HIPEC guidelines. This protocol will be prospectively validated.
CONCLUSIONS: Most respondents were implementing ERAS practices for patients undergoing CRS-HIPEC, though as an extrapolation of colorectal and gynecological guidelines. The adoption of postoperative practices was relatively low compared to other perioperative practices.
© 2021 Geetu Bhandoria et al., published by De Gruyter, Berlin/Boston.

Entities:  

Keywords:  cytoreductive surgery; enhanced recovery after surgery (ERAS); hyperthermic intraperitoneal chemotherapy (HIPEC); perioperative management; peritoneal metastases

Year:  2021        PMID: 34676283      PMCID: PMC8482448          DOI: 10.1515/pp-2021-0117

Source DB:  PubMed          Journal:  Pleura Peritoneum        ISSN: 2364-768X


Introduction

Cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) has been associated with higher morbidity compared to other gastrointestinal oncological procedures, with complications developing up to 90-days after surgery [1, 2]. CRS comprises a spectrum of procedures that can vary from resection of a single peritoneal nodule to complete removal of the parietal peritoneum combined with multiple visceral resections [3]. The metabolic and inflammatory responses to surgery are greatly enhanced after such procedures [4]. Incorporation of enhanced recovery after surgery (ERAS) protocols in the perioperative management of patients undergoing CRS-HIPEC has the potential to cause an early reversal of the pathophysiological cascade and thereby hasten recovery, reduce complications and cost. In recent times, ERAS protocols have shown reproducible benefits in patients undergoing colorectal and gynecological surgeries, and guidelines have been made and are being implemented for major abdominal and extra-abdominal surgical procedures [5], [6], [7], [8], [9], [10]. Elias et al. described the normal postoperative course of patients undergoing CRS-HIPEC [11]. Events like higher pain scores, higher nasogastric tube output, higher peritoneal drain output, and transient diarrhea are often seen after CRS-HIPEC [9, 11], [12], [13]. These patients require longer intensive care admissions and a longer hospital stay, compared to other gastrointestinal surgical procedures. Webb et al. demonstrated a reduction in overall intravenous fluids, postoperative narcotic use, complication rates, and length of stay, after implementation of ERAS protocols in CRS-HIPEC patients [14]. ERAS pathways also provide an opportunity to standardize perioperative practices. An American study from 12 academic institutions showed that variation in perioperative practice patterns existed among measured ERAS pathway process/outcomes. The percentages of variation with each process/outcome measure attributable solely to institutional practices ranged from 0.6 to 66.6% [15]. We conducted this survey to study existing practices about ERAS in patients undergoing CRS-HIPEC in India.

Materials and methods

A group of specialists comprising surgeons, anesthesiologists, and critical care specialists from the members of the Indian Network for Development of Peritoneal Surface Oncology (INDEPSO®) and the Society of Onco-anesthesia and Peri-operative Care (SOAPC®), constituted the authors of this manuscript. The initiative was taken by a core group of three members comprising a peritoneal oncology specialist (AB), one clinician experienced in perioperative management (SLS), and the third having experience with ERAS protocols and surveys (GB). The survey was then sent to the remaining authors who vetted the questionnaire considering the relevance of the questions and their choices, clarity, detail, and lack of ambiguity. The questionnaire was designed based on existing ERAS guidelines on colorectal and gynecological cancer surgery and comprised both open-ended and close-ended questions. ERAS guidelines specific to CRS-HIPEC were not available at the time this survey was conceptualized and were published subsequently [16, 17]. Several perioperative aspects specific to CRS-HIPEC and ERAS pathways were incorporated in the questionnaire (Supplementary Material 1). The online survey was designed using the Survey Monkey® (SVMK, San Mateo, CA, USA) platform. Ethical approval was obtained from the Zydus Hospital Ethics Committee on July 27, 2020. The survey was open from 20th July 2020 to 16th Aug 2020. It took an average of 20 min to answer this 76-question questionnaire. Informed consent was obtained by voluntary participation from respondents. Weekly reminders were sent to those who had not answered the survey. More than 50% of the questionnaire answered was taken as a completed survey. The target audience was Indian clinicians, involved in CRS-HIPEC procedures (surgeons, anesthesiologists, and Intensivists). Electronic mails were used to disburse the survey. The questionnaire comprised of 76 questions on clinicians’ background and experience (n=9), prehabilitation (n=11), preoperative (n=8), intraoperative (n=16), and postoperative management (n=32) of patients undergoing CRS-HIPEC. The preoperative component comprised pre-admission counseling, nutritional intervention, optimization of co-morbid conditions, correction of anemia, initiation of thromboprophylaxis, avoidance of mechanical bowel preparation (MBP) and prolonged fasting, and preoperative carbohydrate loading. Intraoperative elements included fluid and electrolyte management, specific anesthesiology practices like thoracic epidural analgesia, use of short-acting anesthetic agents and opioids, normothermia maintenance, and avoiding the use of drains. Postoperative elements included analgesia with epidural or non-opioid analgesics/short-acting opioids, prevention of nausea and vomiting, early initiation of a regular diet, early active ambulation, early removal of the drains, and oro/nasogastric tubes, thromboprophylaxis, and early discharge from the hospital. Data from the survey were extracted in a comma-separated value (CSV) format. Statistical analysis was performed using Statistical Package for Social Sciences version 24 (SPSS 24, IBM Inc. Chicago IL, U.S.) and Microsoft Office Excel 2016 for Windows (Microsoft, Redmond, WA). Values were expressed in absolute numbers as well as percentages. The chi-square test of significance and Fisher’s exact test were used to compare differences between the responses of clinicians working with a formal institutional protocol with ERAS elements compared to those working without one. ERAS-CRS-HIPEC guidelines were available at the time this survey was analyzed. We performed a comparative subgroup analysis to assess the ‘level of agreement’ of responses with the consensus guidelines. The responses of this survey and the recently published ERAS guidelines were used by the authors to develop a working protocol and checklist, which will be prospectively incorporated in authors’ institutes. The practices that had greater than 70% agreement in the ERAS guidelines and this survey are proposed as ‘essential practices’ (elements) and those that had less than 70% concordance as ‘non-essential elements’, in the working protocol.

Results

A total of 136 out of 206 clinicians contacted answered the survey, generating a 66% response rate. Respondents were surgical oncologists (38.2%), anesthesiologists (29.4%), gynecological oncologists (26.4%), and Intensivists (4.4%). CRS-HIPEC experience of five years or more was reported by 39.7% of respondents, and 60% reported an experience of less than five years. The majority (77.8%) of respondents were affiliated with academic institutions. The majority (95%) of respondents agreed that ERAS could be implemented in CRS-HIPEC patient population. About a third (38.2%) of respondents reported an existing ERAS protocol in their institution (Supplementary Material 2).

Prehabilitation elements

The majority of the respondent counseled patients to stop smoking (81.6%) and alcohol consumption (80.1%) before surgery, encouraged them to exercise (76.4%), and perform incentive spirometry (95%), before surgery. Preoperative anemia is corrected by most (94%) practitioners, and hypoalbuminemia by 89.7%. Immunonutrition is used only by 26.4% of clinicians in this study. Further details are presented in Supplementary Material 3 (Figure 1).
Figure 1:

Prehabilitation practices among the respondents.

Prehabilitation practices among the respondents.

Preoperative and intraoperative elements

MBP was reported used by 84.5% of respondents. Preoperative fasting up to 2 h for liquids was reported by 43.8% of respondents. Half (50.6%) respondents said that patients are kept fasting up to 6–8 h before surgery. The rest of the respondents used longer fasting periods preoperatively. Carbohydrate preloading was reportedly used by 40% of respondents. Thromboprophylaxis was initiated by 92.6% of respondents before surgery. Low molecular weight heparin was the commonest drug used (77.9%) for thromboprophylaxis (Tables 1 and 2).
Table 1:

ERAS practices pertaining to preoperative preparation.

Survey questionTotal number of responses to the question n=136 (%)Number of responses, n (%)
Bowel preparation for CRS-HIPEC

Always

For most patients

Rarely

Never

133 (97.7)77 (56.6)38 (27.9)10 (7.3)8 (5.8)
Type of bowel preparationa

Mechanical bowel preparation

Mechanical + oral antibiotics

Oral antibiotics alone

No bowel preparation

133 (97.7)92 (67.6)25 (18.3)3 (2.2)13 (9.5)
Preoperative fasting for liquids

For 2 h before surgery

For 2–6 h before surgery

For 6–12 h before surgery

For 12–24 h before surgery

133 (97.7)59 (43.8)42 (30.8)28 (20.5)4 (2.9)
Preoperative fasting for solids

For 6 h before surgery

For 6–8 h before surgery

For 8–12 h before surgery

For 12–24 h before surgery

For >24 h before surgery

129 (94.8)25 (18.3)44 (32.3)37 (27.2)18 (13.2)5 (3.6)
Use of carbohydrate preloading

For all patients

For non-diabetics only

Don’t practice

134 (98.5)18 (13.2)37 (27.2)79 (58.0)
Type of carbohydrate loading

Appy juice

Glucose + water solution

Commercial ‘Pre-Carb’ preparations

87 (63.9)36 (26.4)31 (22.7)20 (14.7)
Preoperative thromboprophylaxis

Administered

Not administered

133 (97.7)126 (92.6)7 (5.1)
Preoperative–Intraoperative agents used for thromboprophylaxisa

Low molecular weight heparin

Pneumatic compression devices

Compression stockings

Unfractionated heparin

NA106 (77.9)100 (73.5)93 (67.6)7 (5.1)

aRespondents could choose more than one of the options, the total may thus exceed 100%. NA, not applicable.

Table 2:

ERAS practices pertaining to intraoperative elements.

Survey questionTotal number of responses to the question n=136 (%)Number of responses, n (%)
Multi-modal analgesia approach

Yes

No

132 (97.0)129 (94.8)3 (2.2)
Components of multi-modal analgesiaa

Epidural + opioids + NSAIDs

Epidural + NSAIDs

TAP block + opioids

Opioids + NSAIDs

NA104 (76.4)35 (25.7)18 (13.2)10 (7.3)
Measures to reduce the use of opioids

Yes

No

127 (93.3)62 (45.5)65 (47.7)
Intraoperative fluid management protocol

Early, goal-directed therapy (non-invasive cardiac output monitoring)

Early goal-directed therapy (invasive monitoring + oesophageal Doppler study)

At the discretion of the anesthesia team

Not sure

Not present

133 (97.7)70 (51.4)5 (3.6)48 (35.2)2 (1.4)9 (6.6)
Rate of fluid infusion during CRS phase (standard therapy)

<2 mL/kg/h

2–5 mL/kg/h

5–10 mL/kg/h

>10 mL/kg/h

Other rate

128 (94.1)12 (8.8)46 (33.8)41 (30.1)16 (11.7)13 (9.5)
Rate of fluid infusion during HIPEC phase (standard therapy)

10 mL/kg/h

10–12 mL/kg/h

12–15 mL/kg/h

>15 mL/kg/h

Other rates

123 (90.4)29 (21.3)28 (20.5)31 (22.7)18 (13.2)17 (12.5)
Target urine output during the CRS phase

>0.5 mL/kg/h

>1 mL/kg/h

>2 mL/kg/h

Other rates

129 (94.8)54 (39.7)61 (44.8)12 (8.8)2 (1.4)
Target urine output during the HIPEC phase

>0.5 mL/kg/h

>1 mL/kg/h

>2 mL/kg/h

Other rates

136 (100.0)15 (11.2)55 (40.4)56 (41.7)10 (7.3)
Protocol for monitoring arterial blood gases and lactates

At regular intervals during the CRS phase and more frequently during the HIPEC phase

At the beginning of the procedure and at fixed intervals during the CRS and HIPEC phases both

At the beginning of the procedure and at half-hourly intervals during the HIPEC phase

Others

131 (96.3)38 (27.9)68 (50.0)10 (7.3)15 (11.0)
Core temperature measurement

Yes

No

132 (97.0)123 (90.4)9 (6.6)
Method of measurement of core body temperature

Nasopharyngeal temperature probe

Oesophageal temperature probe

Tympanic membrane probe

Not measured

132 (97.0)64 (47.0)55 (40.4)2 (1.4)11 (8.0)
Methods of prevention of hypothermiaa

Warm intravenous fluids

Forced air blanket devices

Under-body warming mattress

NA109 (80.1)105 (77.2)74 (54.4)
Measures for temperature control during HIPEC

Stop warmer before commencing HIPEC

Cold fluids during HIPEC phase

Ice packs over the neck and axilla

Cool-air blanket

NA111 (81.6)89 (65.4)56 (41.1)38 (27.9)
Is intra-operative transfusion of packed red blood cells done routinely

Yes

No

129 (94.8)55 (40.4)72 (52.9)
Hemoglobin cut-off for blood/packed red blood cells transfusion

7 g%

8 g%

9 g%

10 g%

Other

132 (97.0)30 (22.5)59 (43.3)20 (8.0)11 (8.8)12 (8.8)
Parameters used to decide the quantity of blood transfuseda

Estimated blood loss

Hemodynamic status

Intra-operative hemoglobin level

Preoperative hemoglobin level

Standard protocol

NA10 (80.8)87 (63.9)82 (60.2)51 (37.5)5 (3.6)

aRespondents could choose more than one of the options, the total may thus exceed 100%. NA, not applicable.

ERAS practices pertaining to preoperative preparation. Always For most patients Rarely Never Mechanical bowel preparation Mechanical + oral antibiotics Oral antibiotics alone No bowel preparation For 2 h before surgery For 2–6 h before surgery For 6–12 h before surgery For 12–24 h before surgery For 6 h before surgery For 6–8 h before surgery For 8–12 h before surgery For 12–24 h before surgery For >24 h before surgery For all patients For non-diabetics only Don’t practice Appy juice Glucose + water solution Commercial ‘Pre-Carb’ preparations Administered Not administered Low molecular weight heparin Pneumatic compression devices Compression stockings Unfractionated heparin aRespondents could choose more than one of the options, the total may thus exceed 100%. NA, not applicable. ERAS practices pertaining to intraoperative elements. Yes No Epidural + opioids + NSAIDs Epidural + NSAIDs TAP block + opioids Opioids + NSAIDs Yes No Early, goal-directed therapy (non-invasive cardiac output monitoring) Early goal-directed therapy (invasive monitoring + oesophageal Doppler study) At the discretion of the anesthesia team Not sure Not present <2 mL/kg/h 2–5 mL/kg/h 5–10 mL/kg/h >10 mL/kg/h Other rate 10 mL/kg/h 10–12 mL/kg/h 12–15 mL/kg/h >15 mL/kg/h Other rates >0.5 mL/kg/h >1 mL/kg/h >2 mL/kg/h Other rates >0.5 mL/kg/h >1 mL/kg/h >2 mL/kg/h Other rates At regular intervals during the CRS phase and more frequently during the HIPEC phase At the beginning of the procedure and at fixed intervals during the CRS and HIPEC phases both At the beginning of the procedure and at half-hourly intervals during the HIPEC phase Others Yes No Nasopharyngeal temperature probe Oesophageal temperature probe Tympanic membrane probe Not measured Warm intravenous fluids Forced air blanket devices Under-body warming mattress Stop warmer before commencing HIPEC Cold fluids during HIPEC phase Ice packs over the neck and axilla Cool-air blanket Yes No 7 g% 8 g% 9 g% 10 g% Other Estimated blood loss Hemodynamic status Intra-operative hemoglobin level Preoperative hemoglobin level Standard protocol aRespondents could choose more than one of the options, the total may thus exceed 100%. NA, not applicable. Multimodal analgesia was used by most (94.8%) respondents. Thoracic epidurals, opioids, and non-steroidal anti-inflammatory drugs were the commonest combination (76.4%) used for multimodal analgesia. Goal-directed fluid therapy was reportedly used by 55% of respondents. Most (86%) respondents reported specific intravenous fluid infusion rates and target urine output during CRS and HIPEC phases, each (Table 2). Core body temperature was monitored by 90.4% of respondents. The majority (80%) respondents reported active measures to maintain normothermia during CRS-HIPEC procedures.

Postoperative elements

Intensive care unit (ICU) admissions were reported by 83.8% of respondents for postoperative care. The majority (83%) reported that patients were not extubated immediately post-surgery, and were ventilated electively. Non-invasive ventilation was used by most (71%) respondents during the period of ventilation. The average length of ICU stay for patients was reported as two days by 49.2%, and four days by 30.8% of respondents. Intravenous fluids were stopped by most (82.3%) when the patient started accepting orally (Table 3).
Table 3:

ERAS practices pertaining to post-operative management.b

Survey questionTotal number of responses to the question n=136 (%)Number of responses, n (%)
Immediate postoperative management
Management in the immediate postoperative period

Intensive care unit

High dependency unit

Surgical ward

130 (95.5)114 (83.8)12 (8.8)4 (2.9)
Coagulation monitoring intra and postoperativelya

PT-INR

Fibrinogen levels

Thromboelastography

NA123 (90.4)37 (27.2)23 (16.9)
Post-operative ventilation

Ventilate select patients

Ventilate all patients

Extubate all patients on table

Other responses

134 (98.5)87 (63.9)26 (19.1)14 (10.2)7 (5.1)
Use of non-invasive ventilation (NIV) in the post-operative period

For some

For all

Don’t use

134 (98.5)81 (59.5)16 (11.6)37 (27.2)
Duration of non-invasive ventilation (NIV)

3 days

5 days

As long as clinically indicated

During ICU stay

Other responses

123 (90.4)8 (5.8)7 (5.1)65 (47.7)31 (22.7)12 (8.8)
Average length of stay in the intensive care unit

1 day

2 days

4 days

7 days

Other responses

Missing

133 (97.7)12 (8.8)67 (49.2)42 (30.8)5 (3.6)7 (5.1)3 (2.2)
Fluid and electrolyte balance, diuretics
Rate of fluids administration in the post-operative period

<40 mL/h

40–100 mL/h

>100 mL/h

125 (91.9)3 (2.2)56 (41.1)65 (47.7)
Use of intravenous fluids

12–24 h after surgery

More than 24 h after surgery

Depends on the clinical condition (when oral feeds are tolerated)

134 (98.5)6 (4.4)16 (11.7)112 (82.3)
Frequency of serum calcium, magnesium and phosphate levels monitoring

As clinically indicated

Daily

Alternate day

Other responses

131 (96.3)58 (42.6)46 (33.8)22 (16.1)5 (3.6)
Use of diuretics

Not used

Yes, if clinically indicated

Yes for all

133 (97.7)68 (50.0)62 (45.5)3 (2.2)
Standard protocol for post-operative hypotension, post-HIPEC

Yes

No

127 (93.3)65 (47.7)62 (45.5)
Threshold for adding vasopressor/inotropic support to fluid resuscitation for non-respondersa

Adequate fluid resuscitation done

Evidence of end-organ hypoperfusion (e.g., cardiac symptoms, renal failure, confusion, etc.)

Signs of volume overload (pulmonary oedema, pleural effusions)

Cardiac output numbers

NA95 (69.8)64 (47.5)30 (22.0)31 (22.7)
Perioperative nutritional care
Commencement of pre-emptive enteral feeding

<24 h after surgery

24–48 h after surgery

>48 h after surgery

Other responses

133 (97.7)12 (8.8)62 (45.5)47 (34.5)12 (8.8)
Use of pre-emptive parenteral nutrition

Always

Sometimes

Rarely

Never

132 (97.0)36 (26.4)60 (44.0)30 (22.0)6 (4.4)
Agents used to hasten return of bowel functiona

No agents used

Prokinetic drugs (Cispride/Mosapride)

Bisacodyl suppositories

Chewing gum

Milk of magnesia

Erythromycin

NA71 (52.2)37 (27.2)23 (16.9)19 (13.9)7 (5.1)4 (2.9)
Established protocol for prevention/management of postoperative nausea-vomiting

Yes

No

134 (98.5)97 (71.3)37 (27.2)
Drugs used for prevention/management of postoperative nausea-vomitinga

Metoclopramide

H2 receptor antagonists

Dexamethasone

Aprepitant

Others

NA66 (48.5)63 (46.3)50 (36.7)15 (11.0)2 (1.4)
Commencement of a regular diet

24–48 h after surgery

48–72 h after surgery

>72 h after surgery

Depends on the extend of surgery, number and site of bowel anastomosis

131 (96.3)5 (3.6)16 (11.7)26 (19.11)84 (61.7)
Removal of drains, nasogastric tube, urinary catheter
Use of intra-abdominal drains

Always

Sometimes

Rarely

Never

133 (97.7)112 (82.3)17 (12.5)4 (2.9)0 (0.0)
Removal of drains

Post-operative day 1

Post-operative day 3

Post-operative day 5

Post-operative day 7

When the desirable drain output is reached (or reduces below a pre-specified level)

128 (94.1)2 (1.4)20 (14.7)15 (11.2)2 (1.4)89 (65.4)
Use of inter-costal drains

For all patients undergoing diaphragmatic peritonectomy

Only if diaphragmatic resection

Rarely used

For all HIPEC procedures

Other responses

129 (94.8)54 (39.7)52 (38.2)17 (12.5)4 (2.9)2 (1.4)
Average number of drains (including thoracic), if used

1

2

3

4

Other responses

128 (94.8)14 (10.2)40 (29.2)32 (23.5)28 (20.5)14 (10.2)
Urinary catheter removal after CRS-HIPEC

24–48 h after surgery

48–72 h after surgery

>72 h after surgery

When the patient becomes ambulant

Other responses

131 (96.3)11 (8.0)33 (24.2)29 (21.3)50 (36.7)8 (5.8)
Post-operative use of a nasogastric tube

Always

Sometimes

Rarely

Never

134 (98.5)104 (76.4)24 (17.6)4 (2.9)2 (1.4)
Removal of the nasogastric tube

24 h after surgery

48 h after surgery

72 h after surgery

When oral feeds are tolerated

When the output reduces/bowel function returns

Other responses

131 (96.3)27 (19.8)21 (15.4)5 (3.6)31 (22.7)42 (30.8)5 (3.6)
Thromboprophylaxis, mobilization and discharge
Pharmacological thromboprophylaxis

Yes

No

133 (97.7)132 (97.0)1 (0.7)
Duration of thromboprophylaxis

For 2 weeks after surgery

For 4 weeks after surgery

During the hospital stay alone

During the ICU stay alone

Other responses

130 (95.5)18 (13.2)20 (14.77)70 (51.4)12 (8.8)10 (7.3)
Commencement of mobilization

One the day of surgery

Post-operative day 1

Post-operative day 2

Post-operative day 3

Other responses

131 (96.3)1 (0.7)69 (50.7)46 (33.8)12 (8.8)3 (2.2)
Average hospital stay

<7 days

7–10 days

10–12 days

>12 days

130 (95.5)17 (12.5)61 (44.8)41 (30.1)11 (8.0)

aRespondents could choose more than one of the options, the total may thus exceed 100%. bResponses to three questions are not listed in this table (1 with subjective responses, 2 on ERAS protocols). NA, not applicable.

ERAS practices pertaining to post-operative management.b Intensive care unit High dependency unit Surgical ward PT-INR Fibrinogen levels Thromboelastography Ventilate select patients Ventilate all patients Extubate all patients on table Other responses For some For all Don’t use 3 days 5 days As long as clinically indicated During ICU stay Other responses 1 day 2 days 4 days 7 days Other responses Missing <40 mL/h 40–100 mL/h >100 mL/h 12–24 h after surgery More than 24 h after surgery Depends on the clinical condition (when oral feeds are tolerated) As clinically indicated Daily Alternate day Other responses Not used Yes, if clinically indicated Yes for all Yes No Adequate fluid resuscitation done Evidence of end-organ hypoperfusion (e.g., cardiac symptoms, renal failure, confusion, etc.) Signs of volume overload (pulmonary oedema, pleural effusions) Cardiac output numbers <24 h after surgery 24–48 h after surgery >48 h after surgery Other responses Always Sometimes Rarely Never No agents used Prokinetic drugs (Cispride/Mosapride) Bisacodyl suppositories Chewing gum Milk of magnesia Erythromycin Yes No Metoclopramide H2 receptor antagonists Dexamethasone Aprepitant Others 24–48 h after surgery 48–72 h after surgery >72 h after surgery Depends on the extend of surgery, number and site of bowel anastomosis Always Sometimes Rarely Never Post-operative day 1 Post-operative day 3 Post-operative day 5 Post-operative day 7 When the desirable drain output is reached (or reduces below a pre-specified level) For all patients undergoing diaphragmatic peritonectomy Only if diaphragmatic resection Rarely used For all HIPEC procedures Other responses 1 2 3 4 Other responses 24–48 h after surgery 48–72 h after surgery >72 h after surgery When the patient becomes ambulant Other responses Always Sometimes Rarely Never 24 h after surgery 48 h after surgery 72 h after surgery When oral feeds are tolerated When the output reduces/bowel function returns Other responses Yes No For 2 weeks after surgery For 4 weeks after surgery During the hospital stay alone During the ICU stay alone Other responses One the day of surgery Post-operative day 1 Post-operative day 2 Post-operative day 3 Other responses <7 days 7–10 days 10–12 days >12 days aRespondents could choose more than one of the options, the total may thus exceed 100%. bResponses to three questions are not listed in this table (1 with subjective responses, 2 on ERAS protocols). NA, not applicable. Most (94.7%) respondents used intraabdominal drains. These drains were removed when the output reduced below a subjectively determined volume (65.4% respondents). Most (77.9%) reported using intercostal drains when diaphragmatic surgery/peritonectomy was performed. Urinary catheters were kept up to 72 h by 32.2% of respondents, 36.7% removed these when the patient became ambulant. The majority (84%) used nasogastric tubes in the postoperative period. Thromboprophylaxis was continued in the postoperative period by most (97%) respondents. The average hospital stay was reported between seven to 10 days by 44.8% of respondents, while 10–12 days was reported by another 30%. There were some differences in the practices among clinicians working with and without a formal protocol incorporating ERAS practices. The only statistically significant one was the use of preoperative carbohydrate loading that was more in the ERAS group (p=0.002) (Table 4). The ‘commonest choices among responses’ for ERAS elements were compared with the consensus guidelines. The percentage of agreement was low (50–75%) for postoperative practices like avoiding nasogastric drainage, intra-abdominal drains, and thoracic drains, which was similar to the practices of our respondents (Table 4).
Table 4:

Comparison of responses from clinicians with and without institutional protocols with ERAS elementsa and comparison with the responses of specialists participating in the ERAS consensus guidelines.

Survey questionMost common responseExisting ERAS protocol, n (%)No ERAS protocol, n (%)All patients, n (%)p-Valueb ERAS consensus guidelines (level of agreement (%) amongst the specialists)
Do you use bowel preparation before CRS and HIPECAlways52 (64.1%)25 (48.0%)77 (58.7%)0.22562.5% (for rectal resection)54.2% (not required for colonic resection)
Do you use carbohydrate loading in your preoperative practice?I don’t use carbohydrate loading21 (40.3%)56 (70.05%)77 (58.3%)0.002Preoperative carbohydrate loading should be used (75.0%)
When is a regular diet started routinely after CRS-HIPEC?Depends on the extent of surgery, number and site of bowel anastomosis49 (63.6%)34 (65.3%)83 (64.3%)0.872Solid food should be started on postoperative day 1 (66.5%)
What is your practice for using intra-abdominal drains?Always69 (86.2)42 (80.7)111(84.0)0.3192Intra-abdominal drains should be used (50.0%)
What is your practice for using inter-costal drains?For all patients undergoing diaphragmatic peritonectomy29 (37.6)25 (48.0)54 (41.8)0.701Thoracic drainage should be performed for patients undergoing diaphragmatic surgery (54.2%)
When is the urinary catheter commonly removed after CRS and HIPECWhen the patient starts ambulating28 (35.4)21 (41.1)49 (37.6)0.865Urinary catheter should be removed after 3 days (83.3%)
Do you retain a nasogastric tube post-operatively?Always62 (77.5)40 (79.6)102 (77.2)0.325Nasogastric tube should not be retained in absence of risk factors for delayed gastric emptying (54.2%)
For how long is postoperative thromboprophylaxis continued?During hospital stay only38 (50.0)30 (57.6)68 (53.1)0.174Thromboprophylaxis should be continued for 4 weeks post-operatively (95.8%)

aOnly responses to selected questions have been compared here. bComparison between clinician working with and without a formal ERAS protocol.

Comparison of responses from clinicians with and without institutional protocols with ERAS elementsa and comparison with the responses of specialists participating in the ERAS consensus guidelines. aOnly responses to selected questions have been compared here. bComparison between clinician working with and without a formal ERAS protocol.

Working protocol and checklist

The working protocol (Supplementary Material 4) includes 44 elements that are divided into essential and non-essential elements (Figure 2). Essential elements are those that must be followed in all patients irrespective of the disease extent and nature of surgery. Non-essential elements are those which can be selectively implemented at the discretion of the treating clinicians.
Figure 2:

Essential and non-essential elements in the working protocol for prospective implementation of ERAS practices.

Essential and non-essential elements in the working protocol for prospective implementation of ERAS practices.

Discussion

This survey, addressing ERAS practices about CRS-HIPEC, showed that the majority (91%) of the clinicians reported implementing ERAS practices. Anesthesiologists and critical care specialists who form an integral part of the team managing CRS-HIPEC patients were part of this study. This adds value to this study since they form one of the ‘ERAS champions’ along with surgeons and nurses [18]. Similar surveys in past [19], [20], [21] had invited only surgeons to respond. ERAS practices are gradually being incorporated as institutional protocols. Our study showed that 38% of respondents already have ERAS practices instituted in their protocols. This aligns with a recent international survey among gynecological oncology surgeons [21]. It was encouraging to see that most (91%) other institutes were following some of the ERAS practices, more importantly, as no formal ERAS CRS-HIPEC guidelines were available at the time of this study. Peritoneal surface malignancy is an evolving surgical discipline and is a decade old in India [22]. Most clinicians involved in CRS-HIPEC practice for more than 5 years in India answered this survey.

Prehabilitation

Benefits of prehabilitation have been shown in several recent studies, and these form integral initial elements in an ERAS pathway [23], [24], [25], [26]. It was encouraging to see that most clinicians were following prehabilitation practices in their CRS-HIPEC subset of patients (75–95%). Incentive spirometry was initiated by most (95%) when a decision of surgery was made [27]. Our previous report showed a reduction in respiratory complications in patients undergoing CRS-HIPEC with preoperative spirometry and non-invasive ventilation in the postoperative period [28, 29].

Preoperative elements

The current consensus is to avoid mechanical bowel preparation for major abdominal and pelvic surgeries except for rectal surgeries, though bowel preparation with oral antibiotics is recommended [30]. The majority (86%) of respondents still use bowel preparation for their CRS-HIPEC procedures. In the international consensus, 65.2% recommended MBP for patients undergoing rectal resection, which is low considering that these patients have higher rates of bowel resections and multiple anastomoses. Most of our patients present with a high peritoneal cancer index, that merits multiple bowel resections, and most commonly, a rectal resection [28, 31]. There are two theoretical benefits of bowel preparation – reduction in leak rates and wound infections. Anastomotic leaks after CRS-HIPEC are difficult to manage [32, 33]. This and the possibility of unplanned rectal resections are likely reasons for a more conservative approach. The side-effects of mechanical bowel preparation are patient discomfort, dehydration, and prolonged hospital stay [17]. ‘Modern fasting’ practices were reported as 43.8% for liquids (2 h before surgery) and 50.6% for solids (6–8 h before surgery), respectively [34]. There is still a large scope of improvement in these elements. More robust clinical evidence is needed before avoiding bowel preparation can be systematically incorporated into ERAS practices.

Intraoperative elements

Forty-five% respondents reported that they were actively trying to reduce opioid use, usually by alternative regional analgesia techniques like transversus abdominis plane block, wound infiltration, etc. Similarly, the use of epidural analgesia, which has shown advantages for other surgical procedures, was high (>75.0%) [18]. In the recently published ERAS guidelines, there are many other components like measures for preventing surgical site infections, skin preparation, maintenance of normothermia, optimal fluid management using goal-directed fluid therapy that is already part of the perioperative management protocols [14, 17, 35]. Majority of the respondents followed these practices. The SOAPC has published consensus guidelines for the perioperative management of patients undergoing CRS-HIPEC that already address most of these issues [36]. Some specific measures were not included in our survey questionnaire as they represent routine practices like skin preparation and prophylactic oral antibiotics.

Postoperative management

More than 50% of the respondents favored early extubation, if possible, in the operating room, early mobilization, and early initiation of feeding, which concurs with ERAS practices. But extubation in the operating room or elective ventilation depends on many factors like preoperative pulmonary and cardiac comorbidities, resection of the diaphragm, amount of blood loss during surgery, and hemodynamic stability at the end of surgery [37]. The respondents’ approach was more conservative regarding other practices like avoiding nasogastric drainage or early removal, avoiding/early removal of intraabdominal and thoracic drains, and early removal of the urinary catheter. Once again, this could be attributed to the extent of the surgery. It’s been proposed that nasogastric drainage can be avoided in patients who do not undergo resection of the lesser omentum [14]. In our protocol, these practices are optional, and we will prospectively evaluate the results of these practices using the checklist. Another essential aspect that is difficult to replicate in the Indian subcontinent is early discharge [35]. When the cost is borne by patients directly, both clinicians and patients are more comfortable with a few extra days in the hospital than early discharge, which is less than the cost of taking essential supportive care at another medical facility. Patients coming from smaller towns and remote areas do not have access to the supportive care required following these procedures (supportive fluid therapy, drainage of collections). Traveling back and forth is expensive and inconvenient. The postoperative practices are still conservative and need the maximum transition to ERAS pathways. It has been shown that out of several ERAS elements, postoperative elements have the greatest impact on optimal recovery [37]. However few recent studies have demonstrated that postoperative elements are the most difficult ones to implement [38, 39].

Implementation of ERAS protocol and checking compliance

The working protocol comprises essential and non-essential elements (Figure 2). Compliance of 70% is acceptable when evaluating adherence to ERAS protocols. But this may not be applicable for all elements. Some elements like prehabilitation, shorter duration of fasting, carbohydrate loading, multimodal analgesia, and early ambulation can be implemented in all patients, irrespective of disease extent and surgical complexity (Supplementary Material 4), and the compliance for such elements should be nearly 100%. Implementation of these can lead to a reduction in morbidity and length of stay. Others like avoiding MBP, early removal of drains, and early discharge may be difficult to implement in all patients and more evidence is needed to recommend their routine use. Studies reporting the feasibility of ERAS in patients undergoing CRS have also demonstrated lower compliance for the latter [35, 39]. This division into essential and non-essential elements should make it feasible for more teams to follow these practices. The accompanying checklist is a simple and inexpensive tool to both document and evaluates compliance.

Future directives

Implementation of the protocol and check-list will enable us to devise a final protocol that can be implemented with a high level of compliance at our centers. It will be used to analyze the impact of these practices on morbidity and mortality. Based on the results and accumulating evidence from around the world we hope to be able to create an ‘ideal’ protocol for the Indian centers. The results will also be discussed at clinical meetings and conferences to recruit more centers for the study. Members of both societies will be informed thorough emails and social media platforms about the outcomes of the prospective study. The results will also be published in scientific journals. Our survey was exhaustive considering ERAS practices alone and had a reasonable response rate (>60%). Nearly 100% of the surgeons exclusively involved in the management of peritoneal metastases responded to the survey. This survey serves as a baseline evaluation of the existing practices. The working protocol and checklist can be used by other teams to implement ERAS practices. There are certain weaknesses of our study. Firstly, it is a survey-based study, thus represents clinicians’ opinions. There is always a possible gap between responses and actual practice in a survey-based study. The strengths of our study are that this survey represents the perspectives of anesthesiologists and Intensivists too. Prior surveys have not engaged these practitioners. Our survey is possibly the most exhaustive survey yet on CRS-HIPEC, with 76 questions. We feel this study captures most perioperative elements involved in the CRS-HIPEC subset of patients. The prospective validation of ERAS-CRS-HIPEC guidelines will soon be undertaken, and we would be able to contribute to ever-emerging evidence supporting ERAS.

Conclusions

This national survey demonstrates that the majority of the respondents reported incorporating ERAS practices for patients undergoing CRS-HIPEC. Many of the preoperative and intraoperative practices were being followed. The adoption of several postoperative practices was relatively lower. There is institutional variation in several perioperative practices, and ERAS protocols provide an opportunity to streamline these variations. The working protocol and checklist will formalize the implementation of these practices and evaluate the clinical benefit and safety of ERAS practices. Click here for additional data file.
  38 in total

Review 1.  American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines, 2016 Update.

Authors:  Kristen A Ban; Joseph P Minei; Christine Laronga; Brian G Harbrecht; Eric H Jensen; Donald E Fry; Kamal M F Itani; E Patchen Dellinger; Clifford Y Ko; Therese M Duane
Journal:  J Am Coll Surg       Date:  2016-11-30       Impact factor: 6.113

Review 2.  Guidelines for Perioperative Care for Liver Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations.

Authors:  Emmanuel Melloul; Martin Hübner; Michael Scott; Chris Snowden; James Prentis; Cornelis H C Dejong; O James Garden; Olivier Farges; Norihiro Kokudo; Jean-Nicolas Vauthey; Pierre-Alain Clavien; Nicolas Demartines
Journal:  World J Surg       Date:  2016-10       Impact factor: 3.352

3.  Enhanced Recovery After Surgery (ERAS) in gynecologic oncology: an international survey of peri-operative practice.

Authors:  Geetu Prakash Bhandoria; Prashant Bhandarkar; Vijay Ahuja; Amita Maheshwari; Rupinder K Sekhon; Murat Gultekin; Ali Ayhan; Fuat Demirkiran; Ilker Kahramanoglu; Yee-Loi Louise Wan; Pawel Knapp; Jakub Dobroch; Andrzej Zmaczyński; Robert Jach; Gregg Nelson
Journal:  Int J Gynecol Cancer       Date:  2020-08-04       Impact factor: 3.437

4.  Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced Recovery After Surgery (ERAS®) Society Recommendations - Part II: Postoperative management and special considerations.

Authors:  Martin Hübner; Shigeki Kusamura; Laurent Villeneuve; Ahmed Al-Niaimi; Mohammad Alyami; Konstantin Balonov; John Bell; Robert Bristow; Delia Cortés Guiral; Anna Fagotti; Luiz Fernando R Falcão; Olivier Glehen; Laura Lambert; Lloyd Mack; Tino Muenster; Pompiliu Piso; Marc Pocard; Beate Rau; Olivia Sgarbura; S P Somashekhar; Anupama Wadhwa; Alon Altman; William Fawcett; Jula Veerapong; Gregg Nelson
Journal:  Eur J Surg Oncol       Date:  2020-08-13       Impact factor: 4.424

5.  Guidelines for Perioperative Care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): Enhanced recovery after surgery (ERAS®) Society Recommendations - Part I: Preoperative and intraoperative management.

Authors:  Martin Hübner; Shigeki Kusamura; Laurent Villeneuve; Ahmed Al-Niaimi; Mohammad Alyami; Konstantin Balonov; John Bell; Robert Bristow; Delia Cortés Guiral; Anna Fagotti; Luiz Fernando R Falcão; Olivier Glehen; Laura Lambert; Lloyd Mack; Tino Muenster; Pompiliu Piso; Marc Pocard; Beate Rau; Olivia Sgarbura; S P Somashekhar; Anupama Wadhwa; Alon Altman; William Fawcett; Jula Veerapong; Gregg Nelson
Journal:  Eur J Surg Oncol       Date:  2020-08-25       Impact factor: 4.424

6.  Enhanced recovery after surgery (ERAS®) in gynecologic oncology - Practical considerations for program development.

Authors:  G Nelson; S C Dowdy; J Lasala; G Mena; J Bakkum-Gamez; L A Meyer; M D Iniesta; P T Ramirez
Journal:  Gynecol Oncol       Date:  2017-09-23       Impact factor: 5.482

7.  Mechanical and oral antibiotic bowel preparation versus no bowel preparation for elective colectomy (MOBILE): a multicentre, randomised, parallel, single-blinded trial.

Authors:  Laura Koskenvuo; Taru Lehtonen; Selja Koskensalo; Suvi Rasilainen; Kai Klintrup; Anu Ehrlich; Tarja Pinta; Tom Scheinin; Ville Sallinen
Journal:  Lancet       Date:  2019-08-08       Impact factor: 79.321

8.  Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Dario Baratti; Shigeki Kusamura; Barbara Laterza; Maria Rosaria Balestra; Marcello Deraco
Journal:  World J Gastrointest Oncol       Date:  2010-01-15

9.  "Natural history" of complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

Authors:  D Elias; D Di Pietrantonio; T Boulet; C Honore; S Bonnet; D Goere; N Kohneh-Shahri; B Raynard
Journal:  Eur J Surg Oncol       Date:  2008-03-28       Impact factor: 4.424

10.  Evaluation of Enhanced Recovery After Following a Surgical Protocol for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis.

Authors:  Ozgul Duzgun
Journal:  Med Arch       Date:  2019-10
View more
  2 in total

Review 1.  Considerations for multimodal prehabilitation in women with gynaecological cancers: a scoping review using realist principles.

Authors:  Rhia Kaur Saggu; Phillip Barlow; John Butler; Sadaf Ghaem-Maghami; Cathy Hughes; Pernilla Lagergren; Alison H McGregor; Clare Shaw; Mary Wells
Journal:  BMC Womens Health       Date:  2022-07-19       Impact factor: 2.742

Review 2.  Role of prophylactic HIPEC in non-metastatic, serosa-invasive gastric cancer: a literature review.

Authors:  Aditya R Kunte; Aamir M Parray; Manish S Bhandare; Sohan Lal Solanki
Journal:  Pleura Peritoneum       Date:  2022-07-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.